

ile 5: Biosis Previews(R) 1969-2003/Mar W4
(c) 2003 BIOSIS
*File 5: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.
File 73: EMBASE 1974-2003/Mar W4
(c) 2003 Elsevier Science B.V.
*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.
File 155: MEDLINE(R) 1966-2003/Mar W4
(c) format only 2003 The Dialog Corp.
*File 155: Medline has been reloaded and accession numbers have changed. Please see HELP NEWS 155.
File 399: CA SEARCH(R) 1967-2003/UD=13813
(c) 2003 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set Items Description

? e au=wallner?

Ref	Items	Index-term
E1	4	AU=WALLNER, WILLIAM E.
E2	1	AU=WALLNER, WILLIAM M.
E3	0	*AU=WALLNER?
E4	19	AU=WALLNEROVA Z
E5	3	AU=WALLNEROVA Z.
E6	1	AU=WALLNERT S.F.
E7	1	AU=WALLNET B.C.
E8	1	AU=WALLNHOEFER P
E9	1	AU=WALLNOEER, P.
E10	3	AU=WALLNOEFER A
E11	1	AU=WALLNOEFER ANDREAS
E12	14	AU=WALLNOEFER B

Enter P or PAGE for more

? e au=wallner barbara ?

Ref	Items	Index-term
E1	21	AU=WALLNER B.P.
E2	3	AU=WALLNER BARBARA
E3	0	*AU=WALLNER BARBARA ?
E4	1	AU=WALLNER BARBARA A
E5	6	AU=WALLNER BARBARA C
E6	10	AU=WALLNER BARBARA P
E7	1	AU=WALLNER BENGT
E8	5	AU=WALLNER BERNARD
E9	1	AU=WALLNER BERND
E10	1	AU=WALLNER BERND K
E11	3	AU=WALLNER BERNHARD
E12	11	AU=WALLNER C

Enter P or PAGE for more

? s e1-e6

21	AU=WALLNER B.P.
3	AU=WALLNER BARBARA
0	AU=WALLNER BARBARA ?
1	AU=WALLNER BARBARA A
6	AU=WALLNER BARBARA C
10	AU=WALLNER BARBARA P
41	E1-E6

? s s1 and lfa?

41	S1
16021	LFA?

S2 13 S1 AND LFA?
? rd s2
...completed examining records
S3 12 RD S2 (unique items)
? t s3/3/all

3/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13086443 BIOSIS NO.: 200100293592
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction.
AUTHOR: **Wallner Barbara P(a)**; Cooper Kevin D
AUTHOR ADDRESS: (a)Weston, MA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1241 (3):pNo Pagination Dec. 19, 2000
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

3/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

12187111 BIOSIS NO.: 199900481960
CD2-binding domain of lymphocyte function associated antigen-3.
AUTHOR: **Wallner Barbara P(a)**; Miller Glenn T; Rosa Margaret D
AUTHOR ADDRESS: (a)Department of Psychology, Harvard University, Cambridge, MA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1223 (4):pNO PAGINATION Jun. 22, 1999
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Citation
LANGUAGE: English

3/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

10278203 BIOSIS NO.: 199698733121
Short course single agent therapy with an LFA-3-IgG-1 fusion protein prolongs primate cardiac allograft survival.
AUTHOR: Kaplon Richard J; Hochman Paula S; Michler Robert E; Kwiatkowski Pawel A; Edwards Niloo M; Berger Carole L; Xu He; Meier Werner; **Wallner Barbara P**; Chisholm Patricia; Marboe Charles C(a)
AUTHOR ADDRESS: (a)Dep. Pathol., USC Sch. Med., Hoffman 209, 2011 Zonal Avenue, Los Angeles, CA 90033**USA
JOURNAL: Transplantation (Baltimore) 61 (3):p356-363 1996
ISSN: 0041-1337
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

3/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

08900525 BIOSIS NO.: 199396052026

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses.

AUTHOR: Miller Glenn T; Hochman Paula S; Meier Werner; Tizard Richard; Bixler Sarah A; Rosa Margaret D; **Wallner Barbara P**(a

AUTHOR ADDRESS: (a)Immunol. Pharm. Corp., 610 Lincoln St., Waltham, MA 02154**USA

JOURNAL: Journal of Experimental Medicine 178 (1):p211-222 1993

ISSN: 0022-1007

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

3/3/5 (Item 5 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

08587274 BIOSIS NO.: 199345005349

The increased potency of cross-linked lymphocyte function associated antigen-3 (**LFA-3**) multimers is a direct consequence of changes in valency.

AUTHOR: Chen Ling Ling(a); Pepinsky R Blake; Meier Werner; **Wallner Barbara P**

AUTHOR ADDRESS: (a)Bogen Inc., 14 Cambridge Cent., Cambridge, MA 02142**USA

JOURNAL: Protein Engineering 6 (SUPPL.):p111 1993

CONFERENCE/MEETING: Winter Symposium on Advances in Gene Technology:

Protein Engineering and Beyond Miami, Florida, USA 1993

ISSN: 0269-2139

RECORD TYPE: Citation

LANGUAGE: English

3/3/6 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

06408974 EMBASE No: 1996072731

Short course single agent therapy with an **LFA-3-IgG**inf 1 fusion protein prolongs primate cardiac allograft survival

Kaplon R.J.; Hochman P.S.; Michler R.E.; Kwiatkowski P.A.; Edwards N.M.; Berger C.L.; Xu H.; Meier W.; **Wallner B.P.**; Chisholm P.; Marboe C.C.

Department of Pathology, USC School of Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033 United States

Transplantation (TRANSPLANTATION) (United States) 1996, 61/3 (356-363)

CODEN: TRPLA ISSN: 0041-1337

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

3/3/7 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

04838675 EMBASE No: 1991333411

The increased potency of cross-linked lymphocyte function-associated antigen-3 (**LFA-3**) multimers is a direct consequence of changes in valency

Pepinsky R.B.; Chen L.L.; Meier W.; **Wallner B.P.**

Biogen, Inc., Cambridge, MA 02142 United States

Journal of Biological Chemistry (J. BIOL. CHEM.) (United States) 1991, 266/27 (18244-18249)

CODEN: JBCHA ISSN: 0021-9258

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

3/3/8 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

04814456 EMBASE No: 1991309192
Endothelial cell lymphocyte function-associated antigen-3 and an
unidentified ligand act in concert to provide costimulation to human
peripheral blood CD4sup + T cells
Savage C.O.S.; Hughes C.C.W.; Pepinsky R.B.; **Wallner B.P.**; Freedman
A.S.; Pober J.S.
Department of Pathology, Brigham and Women's Hospital, Harvard Medical
School, Boston, MA 02115 United States
Cellular Immunology (CELL. IMMUNOL.) (United States) 1991, 137/1
(150-163)
CODEN: CLIMB ISSN: 0008-8749
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

3/3/9 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

04627862 EMBASE No: 1991121905
Complementary roles for CD2 and **LFA**-1 adhesion pathways during T
cell activation
Moingeon P.E.; Lucich J.L.; Stebbins C.C.; Recny M.A.; **Wallner B.P.**
; Koyasu S.; Reinherz E.L.
Lab. of Immunobiology, Dana-Farber Cancer Institute, 44 Binney
Street, Boston, MA 02115 United States
European Journal of Immunology (EUR. J. IMMUNOL.) (Germany) 1991, 21/3
(605-610)
CODEN: EJIMA ISSN: 0014-2980
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

3/3/10 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

04259589 EMBASE No: 1990142132
Role of interaction of CD2 molecules with lymphocyte function-associated
antigen 3 in T-cell recognition of nominal antigen
Koyasu S.; Lawton T.; Novick D.; Recny M.A.; Siliciano R.F.; **Wallner**
B.P.; Reinherz E.L.
Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA
02115 United States
Proceedings of the National Academy of Sciences of the United States of
America (PROC. NATL. ACAD. SCI. U. S. A.) (United States) 1990, 87/7
(2603-2507)
CODEN: PNAS A ISSN: 0027-8424
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

3/3/11 (Item 6 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

03961745 EMBASE No: 1989130738

CD2-mediated adhesion facilitates T lymphocyte antigen recognition
function

Moingeon P.; Chang H.-C.; **Wallner B.P.**; Stebbins C.; Frey A.Z.;
Reinherz E.L.

Laboratory of Immunobiology, Dana-Farber Cancer Institute, Boston, MA
02115 United States

Nature (NATURE) (United Kingdom) 1989, 339/6222 (312-314)

CODEN: NATUA ISSN: 0028-0836

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

3/3/12 (Item 7 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

03574799 EMBASE No: 1988024235

Primary structure of lymphocyte function-associated antigen 3 (**LFA**
-3). The ligand of the T lymphocyte CD2 glycoprotein

Wallner B.P.; Frey A.Z.; Tizard R.; Mattaliano R.J.; Hession C.;
Sanders M.E.; Dustin M.L.; Springer T.A.

Biogen Research Corporation, Cambridge, MA 02142 United States

Journal of Experimental Medicine (J. EXP. MED.) (United States) 1987,
166/4 (923-932)

CODEN: JEMEA ISSN: 0022-1007

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

? s s3 and (psoriasis or dermatitis or skin)

12 S3

54444 PSORIASIS

100964 DERMATITIS

926607 SKIN

S4 1 S3 AND (PSORIASIS OR DERMATITIS OR SKIN)

? t s4/3/all

4/3/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13086443 BIOSIS NO.: 200100293592

Method of prophylaxis or treatment of antigen presenting cell driven
skin conditions using inhibitors of the CD2/**LFA**-3
interaction.

AUTHOR: **Wallner Barbara P(a)**; Cooper Kevin D

AUTHOR ADDRESS: (a)Weston, MA**USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1241 (3):pNo Pagination Dec. 19, 2000

MEDIUM: e-file

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Abstract

LANGUAGE: English

? s (lfa(w)3 or lfa3 or lfa3tip) and (psoriasis or dermatitis)

15466 LFA

7079840 3

2694 LFA(W)3

242 LFA3

29 LFA3TIP

54444 PSORIASIS

100964 DERMATITIS

S5 76 (LFA(W)3 OR LFA3 OR LFA3TIP) AND (PSORIASIS OR
DERMATITIS)

? rd s5

...examined 50 records (50)

...completed examining records
S6 45 RD S5 (unique items)
? t s6/3/all

6/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

14067284 BIOSIS NO.: 200300061313
Therapeutic intervention with inhibitors of co-stimulatory pathways in
autoimmune disease.
AUTHOR: Aruffo Alejandro(a); Hollenbaugh Diane(a)
AUTHOR ADDRESS: (a)Immunology and Inflammation Drug Discovery,
Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400,
Princeton, NJ, 08543, USA**USA E-Mail: alejandro.aruffo@bms.com
JOURNAL: Current Opinion in Immunology 13 (6):p683-686 December 2001 2001
MEDIUM: print
ISSN: 0952-7915
DOCUMENT TYPE: Article
RECORD TYPE: Citation
LANGUAGE: English

6/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

14013082 BIOSIS NO.: 200300007111
Alefacept, an immunomodulatory recombinant **LFA-3**/IgG1 fusion
protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+
cells.
AUTHOR: da Silva Antonio J(a); Brickelmaier Margot; Majeau Gerard R; Li
Zhifang; Su Lihe; Hsu Yen-Ming; Hochman Paula S
AUTHOR ADDRESS: (a)Biogen, Inc., 14 Cambridge Center, Cambridge, MA, 02142,
USA**USA E-Mail: antoniodasilva@biogen.com
JOURNAL: Journal of Immunology 168 (9):p4462-4471 May 1 2002 2002
MEDIUM: print
ISSN: 0022-1767
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13941747 BIOSIS NO.: 200200570568
Siplizumab. Antipsoriatic, treatment of transplant rejection.
AUTHOR: Sorbera L A(a); Leeson P A(a); Revel L(a); Bayes M(a)
AUTHOR ADDRESS: (a)Prous Science, 08080, P.O. Box 540, Barcelona**Spain
JOURNAL: Drugs of the Future 27 (6):p558-562 June, 2002
MEDIUM: print
ISSN: 0377-8282
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13673096 BIOSIS NO.: 200200301917

Alefacept (human **LFA-3**/IgG1 fusion protein) is non-immunogenic
in two randomized, placebo-controlled phase III trials for chronic plaque
psoriasis.

AUTHOR: Krueger Gerald(a); Vaishnaw Akshay K
AUTHOR ADDRESS: (a)University of Utah, Salt Lake City, UT**USA
JOURNAL: Journal of Allergy and Clinical Immunology 109 (1 Supplement):p
S320 January, 2002
MEDIUM: print
CONFERENCE/MEETING: 58th Annual Meeting of the American Academy of Allergy,
Asthma and Immunology New York, NY, USA March 01-06, 2002
ISSN: 0091-6749
RECORD TYPE: Citation
LANGUAGE: English

6/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13672962 BIOSIS NO.: 200200301783
Antibody responses to bacteriophage phiX174 and tetanus toxoid are normal
in patients receiving alefacept (human **LFA-3**/IgG1 fusion
protein).
AUTHOR: Gottlieb A B(a); Vaishnaw Akshay K
AUTHOR ADDRESS: (a)UMDNJ, New Brunswick, NJ**USA
JOURNAL: Journal of Allergy and Clinical Immunology 109 (1 Supplement):p
S279 January, 2002
MEDIUM: print
CONFERENCE/MEETING: 58th Annual Meeting of the American Academy of Allergy,
Asthma and Immunology New York, NY, USA March 01-06, 2002
ISSN: 0091-6749
RECORD TYPE: Citation
LANGUAGE: English

6/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13286372 BIOSIS NO.: 200100493521
LFA3TIP affects epidermal CD8+ T cells In Vivo and down-regulates
keratin 16 and Ki-67 expression in the psoriatic plaque.
AUTHOR: Gordon K(a); Nair L(a); Di M(a); Shrager D; Vaishnaw A
AUTHOR ADDRESS: (a)Department of Dermatology, North-western University
Medical School, Chicago, IL**USA
JOURNAL: Journal of Investigative Dermatology 117 (2):p464 August, 2001
MEDIUM: print
CONFERENCE/MEETING: 62nd Annual Meeting of the Society for Investigative
Dermatology Washington, DC, USA May 09-12, 2001
ISSN: 0022-202X
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13133992 BIOSIS NO.: 200100341141
New developments in the treatment of **psoriasis**.
AUTHOR: van de Kerkhof P C M(a)
AUTHOR ADDRESS: (a)Department of Dermatology, UMC St. Radboud, University
Hospital Nijmegen, NL-6500 HB, Nijmegen**Netherlands

JOURNAL: Skin Pharmacology and Applied Skin Physiology 14 (3):p129-135
May-June, 2001
MEDIUM: print
ISSN: 1422-2868
DOCUMENT TYPE: Literature Review
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

13086443 BIOSIS NO.: 200100293592
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction.
AUTHOR: Wallner Barbara P(a); Cooper Kevin D
AUTHOR ADDRESS: (a)Weston, MA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1241 (3):pNo Pagination Dec. 19, 2000
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

6/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

12992762 BIOSIS NO.: 200100199911
Studies on cytokine profiles and DC maturation related to Langerhans cell migration and allergenicity: Ex vivo human explant culture for identifying contact sensitizers.
AUTHOR: Lehe C L(a); Jacobs J J L; Mangal S(a); Elliott G R; Das P K(a)
AUTHOR ADDRESS: (a)Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam**Netherlands
JOURNAL: Immunobiology 203 (1-2):p271-272 November, 2000
MEDIUM: print
CONFERENCE/MEETING: Joint Annual Meeting of the German and Dutch Societies of Immunology Dusseldorf, Germany November 29-December 02, 2000
ISSN: 0171-2985
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

12465487 BIOSIS NO.: 200000218989
The response of chronic plaque **psoriasis** to AmeviveTM (LFA3TIP) and the selective suppression of peripheral memory/effector T cells (CD45RO+) verses naive T cells (CD45RA+) is linked to serum levels of **LFA3TIP**.
AUTHOR: Magilavey D(a); Krueger G G
AUTHOR ADDRESS: (a)Amevive Study Group, Biogen Inc, Cambridge, MA**USA
JOURNAL: Journal of Investigative Dermatology 114 (4):p776 April, 2000
CONFERENCE/MEETING: 61st Annual Meeting of the Society for Investigative Dermatology. Chicago, Illinois, USA May 10-14, 2000
ISSN: 0022-202X

RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

12319834 BIOSIS NO.: 200000040862
Effects of cyclosporin A on immune activation markers in patients with active **psoriasis**.
AUTHOR: Economidou J(a); Barkis J; Demetriou Z; Avgerinou G; Psarra K; Degiannis D; Vareltzidis A; Katsambas A
AUTHOR ADDRESS: (a)Department of Immunology-Histocompatibility, "Evangelismos" Hospital, 45-47 Ipsilantou St., Athens, 10676**Greece
JOURNAL: Dermatology (Basel) 199 (2):p144-148 1999
ISSN: 1018-8665
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

6/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11989657 BIOSIS NO.: 199900270176
Pharmacodynamic effects of **LFA3TIP** (Amevive) in patients with chronic plaque **psoriasis** (CPP): Selective modulation of CD45RO+ lymphocytes.
AUTHOR: Magilavy D(a); Mant T; Norman P; Krueger G; Griffiths C; Ellis C; Barker J; Winkler G; Rogge M
AUTHOR ADDRESS: (a)Biogen, Inc., Cambridge, MA**USA
JOURNAL: Journal of Investigative Dermatology 112 (4):p609 April, 1999
CONFERENCE/MEETING: 60th Annual Meeting of the Society for Investigative Dermatology Chicago, Illinois, USA May 5-9, 1999
ISSN: 0022-202X
RECORD TYPE: Citation
LANGUAGE: English

6/3/13 (Item 13 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

11989656 BIOSIS NO.: 199900270175
Pharmacokinetics of **LFA3TIP** (Amevive) in chronic plaque **psoriasis** patients during repeated once-weekly intravenous administration.
AUTHOR: Rogge M(a); Ellis C; Krueger G; Cooney M; Winkler G; Magilavy D; Sweeney K
AUTHOR ADDRESS: (a)Biogen, Inc., Cambridge, MA**USA
JOURNAL: Journal of Investigative Dermatology 112 (4):p608 April, 1999
CONFERENCE/MEETING: 60th Annual Meeting of the Society for Investigative Dermatology Chicago, Illinois, USA May 5-9, 1999
ISSN: 0022-202X
RECORD TYPE: Citation
LANGUAGE: English

6/3/14 (Item 14 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

11467283 BIOSIS NO.: 199800248615
Targeting CD2 for immunotherapy: Results of a phase 1 trial with a
LFA-3/IgG Fc fusion protein.
AUTHOR: Magilavy Daniel(a); Norman Paul; Majeau Gerard; Knox Steven;
Winkler Gunther; Maclellan Stephen; Sartori Lynn; Cooney Mary; Meier
Werner; Hochman Paula; Rogge Mark
AUTHOR ADDRESS: (a)Biogen Inc., Cambridge, MA 02142**USA
JOURNAL: Journal of Investigative Dermatology 110 (4):p682 April, 1998
CONFERENCE/MEETING: Annual Meeting of the International Investigative
Dermatology Cologne, Germany May 7-10, 1998
SPONSOR: The Society for Investigative Dermatology, Inc.
ISSN: 0022-202X
RECORD TYPE: Citation
LANGUAGE: English

6/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

10626520 BIOSIS NO.: 199699247665
CD40 is functionally expressed on human keratinocytes.
AUTHOR: Denfeld Ralf W(a); Hollenbaugh Diane; Fehrenbach Alexandra; Weiss
Johannes M; Von Leoprechting Achim; Mai Brigit; Voith Ursula; Schoepf
Erwin; Aruffo Alejandro; Simon Jan C
AUTHOR ADDRESS: (a)Dep. Dermatol., Albert-Ludwigs-Universitaet,
Hauptstrasse 7, D-79104 Freiburg**Germany
JOURNAL: European Journal of Immunology 26 (10):p2329-2334 1996
ISSN: 0014-2980
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

10289677 BIOSIS NO.: 199698744595
Adhesion molecules and IL-1 costimulate T lymphocytes in the autologous
MECLR in psoriasis.
AUTHOR: Prens Errol(a); 'T Hooft-Benne Klazina; Tank Bhupendra; Van Damme
Jozef; Van Joost Theodoor; Benner Robbert
AUTHOR ADDRESS: (a)Dep. Immunol., Erasmus Univ. Rotterdam, P.O. Box 1738,
3000 DR Rotterdam**Netherlands
JOURNAL: Archives of Dermatological Research 288 (2):p68-73 1996
ISSN: 0340-3696
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

08904209 BIOSIS NO.: 199396055710
Cyclosporine in atopic dermatitis: Modulation in the expression of
immunologic markers in lesional skin.
AUTHOR: Van Joost T(a); Kozel M M A; Tank B; Troost R; Prens E P
AUTHOR ADDRESS: (a)Dep. of Dermato-Venereology, University Hospital
Rotterdam-Dijkzigt, Dr. Molewaterplein 40, 3015**Netherlands Antilles

JOURNAL: Journal of the American Academy of Dermatology 27 (6 PART 1):p
922-928 1992
ISSN: 0190-9622
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

6/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

08260780 BIOSIS NO.: 000043038053
APC-TARGETED IMMUNOINTERVENTION IN **PSORIASIS** BLOCKADE OF **LFA3**
-CD2 AND ICAM1-LFA1 LIGAND PAIRING BLOCKS AUTOREACTIVITY TO LESIONAL
EPIDERMIS
AUTHOR: GONZALEZ-RAMOS A; WALLNER B P; VOORHEES J J; COOPER K D
AUTHOR ADDRESS: DEP. DERMATOL., UNIV. MICH., ANN ARBOR, MICH.
JOURNAL: 1992 ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY,
BALTIMORE, MARYLAND, USA, APRIL 29-MAY 2, 1992. J INVEST DERMATOL 98 (4).
1992. 556. 1992
CODEN: JIDEA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

6/3/19 (Item 19 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07909727 BIOSIS NO.: 000093008850
INHIBITORY EFFECT OF CYCLOSPORIN A ON ANTIGEN AND ALLOANTIGEN PRESENTING
CAPACITY OF HUMAN EPIDERMAL LANGERHANS CELLS
AUTHOR: TEUNISSEN M B M; DE JAGER M H; KAPSENBERG M L; BOS J D
AUTHOR ADDRESS: DEP. DERMATOL., ROOM K2-209, ACADEMISCH MEDISCH CENTRUM,
UNIVERSITY AMSTERDAM, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, THE NETHERLANDS.
JOURNAL: BR J DERMATOL 125 (4). 1991. 309-316. 1991
FULL JOURNAL NAME: British Journal of Dermatology
CODEN: BJDEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07906295 BIOSIS NO.: 000093005418
DIFFERENTIAL ROLE OF LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGENS IN THE
ACTIVATION OF NICKEL-SPECIFIC PERIPHERAL BLOOD T LYMPHOCYTES
AUTHOR: PRENS E P; BENNE K; VAN JOOST T; BENNER R
AUTHOR ADDRESS: DEP. IMMUNOL., UNIVERSITY HOSP. ROTTERDAM-DIJKZIGT, DR.
MOLEWATERPLEIN 40, 3015 GD ROTTERDAM, THE NETHERLANDS.
JOURNAL: J INVEST DERMATOL 97 (5). 1991. 885-891. 1991
FULL JOURNAL NAME: Journal of Investigative Dermatology
CODEN: JIDEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/21 (Item 21 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

07887644 BIOSIS NO.: 000092136731
OVEREXPRESSION OF EXTRACELLULAR MATRIX RECEPTORS VLA-3 5 AND 6 ON PSORIATIC
KERATINOCYTES
AUTHOR: KELLNER I; KONTER U; STERRY W
AUTHOR ADDRESS: DEP. DERMATOL., UNIV. KIEL, SCHITTENHELMSTR. 7, 2300 KIEL
1, GER.
JOURNAL: BR J DERMATOL 125 (3). 1991. 211-216. 1991
FULL JOURNAL NAME: British Journal of Dermatology
CODEN: BJDEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07638715 BIOSIS NO.: 000092008659
ADHESION MOLECULE EXPRESSION IN PSORIATIC SKIN LESIONS AND THE INFLUENCE OF
CYCLOSPORIN A
AUTHOR: HORROCKS C; DUNCAN J I; OLIVER A M; THOMSON A W
AUTHOR ADDRESS: IMMUNOPATHOLOGY LAB., DEP. PATHOL., UNIV. ABERDEEN MED.
SCH., FORESTERHILL, ABERDEEN AB9 2ZD, UK.
JOURNAL: CLIN EXP IMMUNOL 84 (1). 1991. 157-162. 1991
FULL JOURNAL NAME: Clinical and Experimental Immunology
CODEN: CEXIA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07343098 BIOSIS NO.: 000090123000
INTERACTIONS BETWEEN EPITHELIAL CELLS AND T LYMPHOCYTES ROLE OF ADHESION
MOLECULES
AUTHOR: SINGER K H
AUTHOR ADDRESS: DIV. RHEUMATOL. AND IMMUNOL., BOX 2987, DUKE UNIV. MED.
CENT., DURHAM, N.C. 27710.
JOURNAL: J LEUKOCYTE BIOL 48 (4). 1990. 367-374. 1990
FULL JOURNAL NAME: Journal of Leukocyte Biology
CODEN: JLBIE
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

6/3/24 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11982594 EMBASE No: 2003094286
Effects of alefacept on health-related quality of life in patients with
psoriasis: Results from a randomized, placebo-controlled phase II
trial
Ellis C.N.; Mordin M.M.; Adler E.Y.
Dr. C.N. Ellis, Department of Dermatology, Univ. of Michigan Medical
School, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0314 United
States
American Journal of Clinical Dermatology (AM. J. CLIN. DERMATOL.) (New
Zealand) 2003, 4/2 (131-139)
CODEN: AJCDC ISSN: 1175-0561

DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 29

6/3/25 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11722088 EMBASE No: 2002292692
New developments in the treatment of **psoriasis**
Lebwohl M.
Dr. M. Lebwohl, Department of Dermatology, Mount Sinai Medical Center,
Box 1047, One Gustave L. Levy Place, New York, NY 10029 United States
Archives of Dermatology (ARCH. DERMATOL.) (United States) 2002, 138/5
(686-688)
CODEN: ARDEA ISSN: 0003-987X
DOCUMENT TYPE: Journal ; Editorial
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 14

6/3/26 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11582384 EMBASE No: 2002153920
Alefacept, an immunomodulatory recombinant **LFA-3**/IgG1 fusion
protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2SUP+
cells
Da Silva A.J.; Brickelmaier M.; Majeau G.R.; Li Z.; Su L.; Hsu Y.-M.;
Hochman P.S.
Dr. A.J. Da Silva, Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142
United States
AUTHOR EMAIL: antonio dasilva@biogen.com
Journal of Immunology (J. IMMUNOL.) (United States) 01 MAY 2002,
168/9 (4462-4471)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 54

6/3/27 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

11326733 EMBASE No: 2001338888
Alefacept. Antipsoriatic
Sorbera L.A.; Revel L.; Fernandez R.
L.A. Sorbera, Prous Science, P.O. Box 540, 08080 Barcelona Spain
Drugs of the Future (DRUGS FUTURE) (Spain) 2001, 26/6 (527-532)
CODEN: DRFUD ISSN: 0377-8282
DOCUMENT TYPE: Journal ; Article
LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 32

6/3/28 (Item 5 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

05691185 EMBASE No: 1994092591
Phenotype of Langerhans cells in human afferent skin lymph derived from

allergic contact **dermatitis**

Brand C.U.; Gerber H.A.; Hunziker T.; Schaffner T.; Limat A.; Brathen L.R.

Dermatologische Klinik, Inselspital, 3010 Berne Switzerland
Experimental Dermatology (EXP. DERMATOL.) (Denmark) 1993, 2/6
(274-279)

CODEN: EXDEE ISSN: 0906-6705

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

6/3/29 (Item 6 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

05410987 EMBASE No: 1993179086

Effects of Interferon-Alpha-2b on the clinical course, inflammatory skin infiltrates and peripheral blood lymphocytes in patients with severe atopic eczema

Gruschwitz M.S.; Peters K.-P.; Heese A.; Stosiek N.; Koch H.U.; Hornstein O.P.

Department of Dermatology, University of Erlangen-Nuremberg,
Hartmannstrasse 14, D-W-8520 Erlangen Germany
International Archives of Allergy and Immunology (INT. ARCH. ALLERGY
IMMUNOL.) (Switzerland) 1993, 101/1 (20-30)

CODEN: IAAIE ISSN: 1018-2438

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

6/3/30 (Item 7 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

04330876 EMBASE No: 1990218939

The role of adhesion molecules in epithelial-T-cell interactions in thymus and skin

Singer K.H.; Le P.T.; Denning S.M.; Whichard L.P.; Haynes B.F.

Department of Medicine, Divisions of Rheumatology, Duke University
Medical Center, Durham, NC 27710 United States

Journal of Investigative Dermatology (J. INVEST. DERMATOL.) (United States) 1990, 94/6 SUPPL. (85S-90S)

CODEN: JIDEA ISSN: 0022-202X

DOCUMENT TYPE: Journal; Conference Paper

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

6/3/31 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

10543565 96354986 PMID: 8757303

A novel murine model for the assessment of human CD2-related reagents in vivo.

Ding Y; Qin L; Yang Q; Punch J D; Fox D A; Hochman P S; Bromberg J S

Department of Microbiology, University of Michigan, Ann Arbor, MI 48109, USA.

Journal of immunology (Baltimore, Md. - 1950) (UNITED STATES) Sep 1 1996, 157 (5) p1863-9, ISSN 0022-1767 Journal Code: 2985117R

Contract/Grant No.: AI-32655; AI; NIAID; P60-AR20557; AR; NIAMS

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

6/3/32 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09955592 21873839 PMID: 11881524
Alefacept. Amevive, BG 9273, human **LFA-3**/Igg fusion protein,
LFA 3, **LFA 3** TIP **LFA 3**/CD2, **LFA-**
3/Igg fusion protein, **LFA3TIP**, recombinant **LFA-3**
/Igg1 human fusion protein, recombinantly engineered LFA-1/Igg1 human
fusion protein.
Drugs in R&D (New Zealand) 2002, 3 (1) p21-4, ISSN 1174-5886
Journal Code: 100883647
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/33 (Item 3 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09662559 21451770 PMID: 11569937
Alefacept (Biogen).
Bashir S J; Maibach H I
Department of Dermatology, University of California, San Francisco
94143-0989, USA. saqib@itsa.ucsf.edu
Current opinion in investigational drugs (London, England - 2000) (England) May 2001, 2 (5) p631-4, ISSN 1472-4472 Journal Code:
100965718
Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

6/3/34 (Item 4 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

08447915 95136104 PMID: 7834504
[Cutaneous immune system]
Le systeme immunitaire cutane.
Schmitt D
INSERM Unite 346, Clinique Dermatologique, Hopital Edouard-Herriot, Lyon,
France.
Comptes rendus des seances de la Societe de biologie et de ses filiales (FRANCE) 1994, 188 (3) p207-21, ISSN 0037-9026 Journal Code: 7505439
Document type: Journal Article; Review; Review, Tutorial ; English
Abstract
Languages: FRENCH
Main Citation Owner: NLM
Record type: Completed

6/3/35 (Item 5 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

08051361 94117099 PMID: 7507088
In vitro primary sensitization and restimulation of hapten-specific T
cells by fresh and cultured human epidermal Langerhans' cells.

Moulon C; Peguet-Navarro J; Courtellemont P; Redziniak G; Schmitt D
Laboratoire Peau Humaine et Immunité, INSERM U346, Hôpital E. Herriot,
Lyons, France.

Immunology (ENGLAND) Nov 1993, 80 (3) p373-9, ISSN 0019-2805
Journal Code: 0374672

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

6/3/36 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

137246527 CA: 137(17)246527q PATENT

Multivalent MHC constructs: Immunoanalysis, diagnosis and therapy

INVENTOR(AUTHOR): Winther, Lars; Petersen, Lars Oestergaard; Buus, Soeren
; Schoeller, Joergen; Ruub, Erik; Aamellem, Oeystein

LOCATION: Den.

ASSIGNEE: Dako A/S; Dynal Biotech Asa

PATENT: PCT International ; WO 200272631 A2 DATE: 20020919

APPLICATION: WO 2002DK169 (20020313) *DK 2001435 (20010314) *DK 2001436
(20010314) *DK 2001441 (20010314) *US PV275470 (20010314) *US PV275448
(20010314) *US PV275447 (20010314)

PAGES: 304 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-014/705A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES;
FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ;
LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH;
PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG;
US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG DESIGNATED REGIONAL: GH; GM; KE
; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI;
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN;
GQ; GW; ML; MR; NE; SN; TD; TG

6/3/37 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

137231367 CA: 137(16)231367p PATENT

Anti-CD2 antibodies or CD2 antagonists and immunomodulating agents for
preventing or treating inflammatory or autoimmune disorders

INVENTOR(AUTHOR): Dingivan, Christine

LOCATION: USA

ASSIGNEE: Medimmune, Inc.

PATENT: PCT International ; WO 200269904 A2 DATE: 20020912

APPLICATION: WO 2002US6761 (20020304) *US PV273098 (20010302) *US
PV346918 (20011019)

PAGES: 189 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-000/

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ;
CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; ES; FI; GB; GD; GE; GH;
GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;
LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM; PH; PL; PT; RO; RU; SD; SE;
SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZM; ZW; AM;
AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ
; SD; SL; SZ; TZ; UG; ZM; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML;
MR; NE; SN; TD; TG

6/3/38 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

137168288 CA: 137(12)168288w PATENT
Methods for treating or preventing skin disorders using CD2-binding
agents
INVENTOR(AUTHOR): Vaishnaw, Akshay K.; Cooper, Kevin D.; Shrager, Daniel;
McCormick, Thomas S.
LOCATION: USA
ASSIGNEE: Biogen, Inc.
PATENT: PCT International ; WO 200260480 A1 DATE: 20020808
APPLICATION: WO 2002US2314 (20020125) *US PV265964 (20010201)
PAGES: 68 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;
A61K-039/00B; A61K-038/00B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU;
AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC;
EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR;
KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; OM;
PH; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TN; TR; TT; TZ; UA; UG;
US; UZ; VN; YU; ZA; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZM; ZW;
AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR;
BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/39 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

137072413 CA: 137(6)72413g JOURNAL
Selective targeting of T cell subsets: focus on alefacept - a remittive
therapy for psoriasis
AUTHOR(S): Krueger, Gerald G.
LOCATION: Department of Dermatology, University of Utah Health Sciences
Center, Salt Lake City, UT, 84132, USA
JOURNAL: Expert Opin. Biol. Ther. (Expert Opinion on Biological Therapy)
DATE: 2002 VOLUME: 2 NUMBER: 4 PAGES: 431-441 CODEN: EOBT2 ISSN:
1471-2598 LANGUAGE: English PUBLISHER: Ashley Publications Ltd.

6/3/40 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

136243994 CA: 136(16)243994h PATENT
Reducing the content of cells in a biological sample
INVENTOR(AUTHOR): Mahiout, Arezki
LOCATION: UK,
ASSIGNEE: Allied Therapeutics Limited
PATENT: PCT International ; WO 200224307 A2 DATE: 20020328
APPLICATION: WO 2001GB4126 (20010914) *GB 200022748 (20000915)
PAGES: 56 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: B01D-039/16A;
A61M-001/38B; A61K-035/14B; A61P-019/02B; A61P-017/00B; A61P-003/10B;
A61P-033/00B; A61P-031/12B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU;
AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC;
EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR;
KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PH;
PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; US; UZ;
VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH
; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES;
FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA;
GN; GQ; GW; ML; MR; NE; SN; TD; TG

6/3/41 (Item 6 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136165569 CA: 136(11)165569g JOURNAL
Alefacept
AUTHOR(S): Sorbera, L. A.; Revel, L.; Fernandez, R.
LOCATION: Prous Science, Barcelona, Spain, 08080
JOURNAL: Drugs Future DATE: 2001 VOLUME: 26 NUMBER: 6 PAGES: 527-532
CODEN: DRFUD4 ISSN: 0377-8282 LANGUAGE: English PUBLISHER: Prous
Science

6/3/42 (Item 7 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

132221334 CA: 132(17)221334h PATENT
Method of modulating memory effector T-cells and compositions
INVENTOR(AUTHOR): Magilavy, Daniel
LOCATION: USA
ASSIGNEE: Biogen, Inc.
PATENT: PCT International ; WO 200012113 A2 DATE: 20000309
APPLICATION: WO 99US20026 (19990831) *US 98456 (19980831)
PAGES: 76 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-038/00A
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;
CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GE; GH; GM; HR; HU; ID; IL; IS; JP;
KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO;
NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ;
VN; YU; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM
; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;
GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR;
NE; SN; TD; TG

6/3/43 (Item 8 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

128060716 CA: 128(6)60716j PATENT
MHC class II antigen presentation systems for CD4+ T-cell activation,
differentiation, and adoptive immunotherapy
INVENTOR(AUTHOR): Webb, Susan R.; Winqvist, Ola; Karlsson, Lars; Jackson,
Michael R.; Peterson, Per A.
LOCATION: USA
ASSIGNEE: Scripps Research Institute; Webb, Susan R.; Winqvist, Ola;
Karlsson, Lars; Jackson, Michael R.; Peterson, Per A.
PATENT: PCT International ; WO 9746256 A1 DATE: 19971211
APPLICATION: WO 97US8697 (19970522) *US 18175 (19960523)
PAGES: 141 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/385A;
A61K-045/05B; A61K-048/00B; C07K-014/705B DESIGNATED COUNTRIES: AL; AM; AT
; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB;
GE; GH; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD;
MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TR;
TT; UA; UG; US; UZ; VN; YU; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM
DESIGNATED REGIONAL: GH; KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES;
FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN;
ML; MR; NE; SN; TD; TG

6/3/44 (Item 9 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

126017804 CA: 126(2)17804h PATENT
Human antibodies derived from immunized xenomice

INVENTOR(AUTHOR): Kucherlapati, Raju; Jakobovits, Aya; Klapholz, Sue;
Brenner, Daniel G.; Capon, Daniel J.
LOCATION: USA
ASSIGNEE: Cell Genesys, Inc.
PATENT: PCT International ; WO 9634096 A1 DATE: 19961031
APPLICATION: WO 95US5500 (19950428)
PAGES: 64 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/00A
DESIGNATED COUNTRIES: AU; CA; FI; HU; JP; KR; NO; NZ
DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;
NL; PT; SE

6/3/45 (Item 10 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

119179182 CA: 119(17)179182m PATENT
prophylaxis or treatment of antigen-presenting cell-driven skin
conditions using inhibitors of the CD2/LFA-3 interaction
INVENTOR(AUTHOR): Wallner, Barbara P.; Cooper, Kevin D.
LOCATION: USA
ASSIGNEE: Biogen, Inc.
PATENT: PCT International ; WO 9306866 A2 DATE: 930415
APPLICATION: WO 92US8755 (921006) *US 770969 (911007) *US 862022 (920402)
PAGES: 59 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;
A61K-039/02B; A61K-039/395J; A61K-037/02J DESIGNATED COUNTRIES: AU; CA; JP
; KR DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU;
MC; NL; SE
? t s6/7/17-23,22,30,32

6/7/17 (Item 17 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

08904209 BIOSIS NO.: 199396055710
Cyclosporine in atopic **dermatitis**: Modulation in the expression of
immunologic markers in lesional skin.
AUTHOR: Van Joost T(a); Kozel M M A; Tank B; Troost R; Prens E P
AUTHOR ADDRESS: (a)Dep. of Dermato-Venereology, University Hospital
Rotterdam-Dijkzigt, Dr. Molewaterplein 40, 3015**Netherlands Antilles

JOURNAL: Journal of the American Academy of Dermatology 27 (6 PART 1):p
922-928 1992
ISSN: 0190-9622
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Background: In previous studies, oral cyclosporine was highly
effective in the treatment of patients with severe atopic
dermatitis. In this study seven patients with severe and
therapy-resistant atopic **dermatitis** underwent therapy with
cyclosporine, 5 mg/kg/day, for 6 weeks. Objective: The effect of
cyclosporine on the expression of cytokines, which probably play a role
in this disease, was examined. Methods: The study was performed with a
panel of antibodies as markers of inflammatory cells, adhesion molecules,
and cytokines (interferon-gamma (IFN-gamma), tumor necrosis factor-alpha
(TNF-alpha) and interleukins 1-alpha, 1-beta, and 8 (IL-1-alpha,
IL-1-beta, and IL-8, respectively)). They were visualized by indirect
immunoperoxidase techniques. Results: After 2 weeks of cyclosporine
therapy, a reduction of 60% in the disease (severity and extent) was
observed. This reduction was 89% after 4 weeks and 90% after 6 weeks of
therapy. Results of indirect immunoperoxidase stains performed on
lesional skin sections after 2 weeks of treatment showed statistically

significant reduced numbers of CD14+, CD25 (IL-2R+) and IL-8+ inflammatory cells in the dermis and CD36(OKM5)+ cells in both the epidermis and dermis. The number of cells expressing IFN-gamma and TNF-alpha, assumed to be the products of the helper T-cell (TH) 1 subset, was unaltered despite the impressive clinical benefit observed. Keratinocytes in lesional atopic skin did not express intercellular adhesion molecule type 1 (ICAM-1). The expression of the adhesion molecules ICAM-1, lymphocyte function-associated (LFA) type 1, and LFA-3 on inflammatory cells also remained unaffected by cyclosporine treatment. Conclusion: A statistically significant reduction in the number of activated T cells and in the number of cells expressing the IL-2 receptor (CD25) paralleled a marked improvement in the disease and supports the view that atopic **dermatitis** is based on a T-cell-mediated immune inflammation.

6/7/18 (Item 18 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

08260780 BIOSIS NO.: 000043038053
APC-TARGETED IMMUNOINTERVENTION IN **PSORIASIS** BLOCKADE OF **LFA3**
-CD2 AND ICAM1-LFA1 LIGAND PAIRING BLOCKS AUTOREACTIVITY TO LESIONAL
EPIDERMIS
AUTHOR: GONZALEZ-RAMOS A; WALLNER B P; VOORHEES J J; COOPER K D
AUTHOR ADDRESS: DEP. DERMATOL., UNIV. MICH., ANN ARBOR, MICH.
JOURNAL: 1992 ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY,
BALTIMORE, MARYLAND, USA, APRIL 29-MAY 2, 1992. J INVEST DERMATOL 98 (4).
1992. 556. 1992
CODEN: JIDEA
DOCUMENT TYPE: Meeting
RECORD TYPE: Citation
LANGUAGE: ENGLISH

6/7/19 (Item 19 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07909727 BIOSIS NO.: 000093008850
INHIBITORY EFFECT OF CYCLOSPORIN A ON ANTIGEN AND ALLOANTIGEN PRESENTING
CAPACITY OF HUMAN EPIDERMAL LANGERHANS CELLS
AUTHOR: TEUNISSEN M B M; DE JAGER M H; KAPSENBERG M L; BOS J D
AUTHOR ADDRESS: DEP. DERMATOL., ROOM K2-209, ACADEMISCH MEDISCH CENTRUM,
UNIVERSITY AMSTERDAM, MEIBERGDREEF 9, 1105 AZ AMSTERDAM, THE NETHERLANDS.
JOURNAL: BR J DERMATOL 125 (4). 1991. 309-316. 1991
FULL JOURNAL NAME: British Journal of Dermatology
CODEN: BJDEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: The effect of cyclosporin A (CyA) on the capacity of human epidermal Langerhans cells (LC) to stimulate allogeneic T cells or to present antigen to autologous T cells was investigated. Preparations of LC enriched by discontinuous density gradient centrifugation were pulsed for 2 or 16 h with graded doses (5-5000 ng/ml) of CyA prior to co-culture with T cells. Pretreatment of LC with CyA resulted in a dose-dependent decrease of the functional capacity of LC to stimulate T cells. This inhibition (up to 90%), already achieved after a pulse of 2 h. was not due to a cytotoxic effect of the drug and appeared to be reversible. The possibility that CyA exerted its efficient indirectly on T cells via release of CyA from LC into the supernatant during co-culture was excluded. The suppression of immunostimulatory function was a direct effect of the drug on LC. CyA did not affect the production by LC of IL-1

or prostaglandin, nor the expression of MHC class II products HLA-D and RFD1 or adhesion molecules ICAM-1 and LFA-3. The results suggest that inhibition of contact allergic skin reactions by CyA may be due in part to an impairment of the function of LC.

6/7/20 (Item 20 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07906295 BIOSIS NO.: 000093005418
DIFFERENTIAL ROLE OF LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGENS IN THE
ACTIVATION OF NICKEL-SPECIFIC PERIPHERAL BLOOD T LYMPHOCYTES
AUTHOR: PRENS E P; BENNE K; VAN JOOST T; BENNER R
AUTHOR ADDRESS: DEP. IMMUNOL., UNIVERSITY HOSP. ROTTERDAM-DIJKZIGT, DR.
MOLEWATERPLEIN 40, 3015 GD ROTTERDAM, THE NETHERLANDS.
JOURNAL: J INVEST DERMATOL 97 (5). 1991. 885-891. 1991
FULL JOURNAL NAME: Journal of Investigative Dermatology
CODEN: JIDEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: The possible role(s) of the adhesion molecules LFA-1.alpha. (CD11a), LFA-1.beta. (CD18), ICAM-1 (CD54), CD2 (T11, LFA-2), and LFA-3 (CD58) in the in vitro activation of nickel-specific peripheral blood (PB) T lymphocytes was studied. For this purpose, monoclonal antibodies (MoAb) to these markers were used. Both LFA-2 and LFA-3 appeared to be consistently involved, whereas LFA-1 was inconsistently involved. In studies using antigen-presenting cells (APC) isolated from peripheral blood to present nickel, anti-LFA-1.alpha. and/or LFA-1.beta. MoAb partially inhibited the in vitro activation of nickel-specific T lymphocytes in nine of 42 patients allergic to nickel. In the other 33 patients variable results, ranging from a slight increase or inhibition of proliferation to no inhibition at all, was observed, in particular when different anti-LFA-1.alpha. MoAb were added to the cultures. In those patients who showed no inhibition when anti-LEA-1 (.alpha. and .beta.) MoAb were added, no inhibition was also observed when a mixture of anti-LFA-1 (.alpha. and .beta.) and ICAM-1 MoAb were added to the cultures. Similar results were also obtained using epidermal APC. In control experiments the various anti-LFA-1 (.alpha. and .beta.) MoAb effectively inhibited the tetanus toxoid and Con-A induced T-lymphocyte proliferation as well as the spontaneous aggregation of the JY cell line. Anti-CD2 and anti-LFA-3 MoAb strongly inhibited the proliferative responses of nickel-specific peripheral blood T lymphocytes from all 42 patients. These results indicated that the receptor-ligand interaction between CD2 and LFA-3 is essential for in vitro activation of nickel-specific peripheral blood T lymphocytes. This activation, however, does not regularly involve LFA-1 molecules on T lymphocytes. The involvement of LFA-1 in the activation of nickel-specific T lymphocytes correlated positively with high patch test scores to nickel and the disease activity in contact dermatitis patients.

6/7/21 (Item 21 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07887644 BIOSIS NO.: 000092136731
OVEREXPRESSION OF EXTRACELLULAR MATRIX RECEPTORS VLA-3 5 AND 6 ON PSORIATIC KERATINOCYTES
AUTHOR: KELLNER I; KONTER U; STERRY W
AUTHOR ADDRESS: DEP. DERMATOL., UNIV. KIEL, SCHITTENHELMSTR. 7, 2300 KIEL 1, GER.

JOURNAL: BR J DERMATOL 125 (3). 1991. 211-216. 1991
FULL JOURNAL NAME: British Journal of Dermatology
CODEN: BJDEA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: The potential role of adhesion molecules in the pathophysiology of **psoriasis** was investigated and the pattern of expression of the cell-surface receptors ICAM-1, **LFA-3**, and VLA-1, 2, 3, 4, 5 and 6 was determined in biopsies of skin from patients with **psoriasis** (n = 12) and from normal skin (n = 12). There were no differences in the intensity or localization of the adhesion molecules VLA-1, 2 and 4 and **LFA-3**. In contrast, VLA-3 and VLA-6, which are restricted to the basal keratinocytes in normal skin, were overexpressed in the spinous cells in psoriatic skin. ICAM-1 and VLA-5, which are not expressed by keratinocytes in normal skin, were focally induced, especially in cells above elongated rete ridges and where there was an infiltrate with intraepidermal granulocytes and lymphocytes.

6/7/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07638715 BIOSIS NO.: 000092008659
ADHESION MOLECULE EXPRESSION IN PSORIATIC SKIN LESIONS AND THE INFLUENCE OF CYCLOSPORIN A
AUTHOR: HORROCKS C; DUNCAN J I; OLIVER A M; THOMSON A W
AUTHOR ADDRESS: IMMUNOPATHOLOGY LAB., DEP. PATHOL., UNIV. ABERDEEN MED. SCH., FORESTERHILL, ABERDEEN AB9 2ZD, UK.
JOURNAL: CLIN EXP IMMUNOL 84 (1). 1991. 157-162. 1991
FULL JOURNAL NAME: Clinical and Experimental Immunology
CODEN: CEXIA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Normal skin of healthy individuals and both lesional and uninvolved skin from patients with **psoriasis** before and after receiving cyclosporin A (CsA; 2.5 or 5 mg/kg per day) was examined by immunocytochemistry for differences in expression of adhesion-relevant epitopes. Normal, lesional and uninvolved skin all showed staining of basal keratinocytes for CD29 (the common .beta. chain of the .beta.1-integrin family). No other adhesion molecule investigated was detected on structural components of normal skin. In uninvolved skin, weak expression of CD54 (intercellular adhesion molecule 1, ICAM-1) was noted on vascular endothelium. Uninvolved keratinocytes were found to stain with anti-CD58 (leukocyte function-associated antigen 3, **LFA-3**) and there was weak expression of CD11b (.alpha. chain of complement C3bi receptor) and CD11c (.alpha. chain of p150, 95 molecule) but not CD11a (leukocyte function-associated antigen 1, **LFA-1**, .alpha. chain) on those cells. In lesional skin, in addition to expression of CD58, there was also enhanced expression of CD11c. Weak expression of CD54 on keratinocytes was also observed. Lesional blood vessels were found to stain strongly with anti-CD54, CD29 and CD58. CD11a was expressed only on infiltrating mononuclear cells. CsA treatment produced marked clinical improvement, accompanied by the loss of CD54 expression on keratinocytes. However, despite the loss of T cells from lesional skin with CsA treatment, CD54 persisted on blood vessels. CsA was found to have no effect on keratinocyte expression of CD29, CD58 or CD11b and c. The persistence of CD54 on vascular endothelium and of adhesion molecule expression on keratinocytes, despite resolution of the skin lesions, may explain the universal and rapid recurrence of **psoriasis** on cessation of CsA administration.

6/7/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07343098 BIOSIS NO.: 000090123000
INTERACTIONS BETWEEN EPITHELIAL CELLS AND T LYMPHOCYTES ROLE OF ADHESION
MOLECULES
AUTHOR: SINGER K H
AUTHOR ADDRESS: DIV. RHEUMATOL. AND IMMUNOL., BOX 2987, DUKE UNIV. MED.
CENT., DURHAM, N.C. 27710.
JOURNAL: J LEUKOCYTE BIOL 48 (4). 1990. 367-374. 1990
FULL JOURNAL NAME: Journal of Leukocyte Biology
CODEN: JLBIE
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Cell-cell interaction is critical for normal T cell development and function. A number of adhesion molecules important in T cell interactions with other cell types have been defined. This paper reviews the role of two adhesion pathways, CD2/LFA-3 and LFA-1/ICAM-1, in T cell interactions with epithelial cells of the thymus and skin. While thymic epithelium-T cell interactions are mediated by both the LFA-1/ICAM-1 pathway and the CD2/LFA-3 pathway, epidermal-T cell interactions are mediated primarily by the LFA-1/ICAM-1 pathway. Although ICAM-1 is not expressed in vivo on epidermal keratinocytes in normal skin, ICAM-1 is expressed by epidermal keratinocytes at the site of T cell infiltration in inflammatory **dermatitis**. ICAM-1 is expressed in vivo on thymic epithelium. These antigen independent adhesion molecules play an important role in the cell-cell interactions associated with T cell differentiation and function.

6/7/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

07638715 BIOSIS NO.: 000092008659
ADHESION MOLECULE EXPRESSION IN PSORIATIC SKIN LESIONS AND THE INFLUENCE OF
CYCLOSPORIN A
AUTHOR: HORROCKS C; DUNCAN J I; OLIVER A M; THOMSON A W
AUTHOR ADDRESS: IMMUNOPATHOLOGY LAB., DEP. PATHOL., UNIV. ABERDEEN MED.
SCH., FORESTERHILL, ABERDEEN AB9 2ZD, UK.
JOURNAL: CLIN EXP IMMUNOL 84 (1). 1991. 157-162. 1991
FULL JOURNAL NAME: Clinical and Experimental Immunology
CODEN: CEXIA
RECORD TYPE: Abstract
LANGUAGE: ENGLISH

ABSTRACT: Normal skin of healthy individuals and both lesional and uninvolved skin from patients with **psoriasis** before and after receiving cyclosporin A (CsA; 2.5 or 5 mg/kg per day) was examined by immunocytochemistry for differences in expression of adhesion-relevant epitopes. Normal, lesional and uninvolved skin all showed staining of basal keratinocytes for CD29 (the common .beta. chain of the .beta.1-integrin family). No other adhesion molecule investigated was detected on structural components of normal skin. In uninvolved skin, weak expression of CD54 (intercellular adhesion molecule 1, ICAM-1) was noted on vascular endothelium. Uninvolved keratinocytes were found to stain with anti-CD58 (leukocyte function-associated antigen 3, **LFA-3**) and there was weak expression of CD11b (.alpha. chain of complement C3bi receptor) and CD11c (.alpha. chain of p150, 95 molecule) but not CD11a (leukocyte function-associated antigen 1, LFA-1, .alpha.

chain) on those cells. In lesional skin, in addition to expression of CD58, there was also enhanced expression of CD11c. Weak expression of CD54 on keratinocytes was also observed. Lesional blood vessels were found to stain strongly with anti-CD54, CD29 and CD58. CD11a was expressed only on infiltrating mononuclear cells. CsA treatment produced marked clinical improvement, accompanied by the loss of CD54 expression on keratinocytes. However, despite the loss of T cells from lesional skin with CsA treatment, CD54 persisted on blood vessels. CsA was found to have no effect on keratinocyte expression of CD29, CD58 or CD11b and c. The persistence of CD54 on vascular endothelium and of adhesion molecule expression on keratinocytes, despite resolution of the skin lesions, may explain the universal and rapid recurrence of **psoriasis** on cessation of CsA administration.

6/7/30 (Item 7 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

04330876 EMBASE No: 1990218939

The role of adhesion molecules in epithelial-T-cell interactions in thymus and skin

Singer K.H.; Le P.T.; Denning S.M.; Whichard L.P.; Haynes B.F.
Department of Medicine, Divisions of Rheumatology, Duke University
Medical Center, Durham, NC 27710 United States
Journal of Investigative Dermatology (J. INVEST. DERMATOL.) (United
States) 1990, 94/6 SUPPL. (85S-90S)
CODEN: JIDEA ISSN: 0022-202X
DOCUMENT TYPE: Journal; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Interaction of T lymphocytes with other cell types is important for normal T-cell development and function. Recently, a number of adhesion molecules important in T-cell interactions with other cell types have been defined. In this paper we review the role of two adhesion pathways, CD2/**LFA-3** and LFA-1/ICAM-1, in T-cell interactions with epithelial cells of the thymus and skin. While thymic epithelium - T-cell interactions were mediated by both the LFA-1/ICAM-1 pathway and the CD2/**LFA-3** pathway, epidermal-T-cell interactions were mediated primarily by the LFA-1/ICAM-1 pathway. Although ICAM-1 was not expressed in vivo on epidermal keratinocytes in normal skin, ICAM-1 was expressed by epidermal keratinocytes at the site of T-cell infiltration in inflammatory **dermatitis**. ICAM-1 was expressed in vivo on thymic epithelium. Both **LFA-3** and ICAM-1 were expressed on epithelial cells of thymus and skin early on in fetal ontogeny. These antigen-independent adhesion molecules play an important role in the cell-cell interactions associated with T-cell differentiation and function.

6/7/32 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09955592 21873839 PMID: 11881524

Alefacept. Amevive, BG 9273, human **LFA-3**/IgG fusion protein, **LFA-3**, **LFA-3** TIP **LFA-3**/CD2, **LFA-3**/IgG fusion protein, **LFA3TIP**, recombinant **LFA-3**/IgG1 human fusion protein, recombinantly engineered LFA-1/IgG1 human fusion protein.

Drugs in R&D (New Zealand) 2002, 3 (1) p21-4, ISSN 1174-5886
Journal Code: 100883647

Document type: Journal Article; Review; Review, Tutorial
Languages: ENGLISH
Main Citation Owner: NLM

Record type: Completed
(10 Refs.)

Record Date Created: 20020307

Record Date Completed: 20020903

?